Bengaluru teacher Shyamala Ganesh, the former director of the Japanese Language School, will be conferred the Order of the Rising Sun, Gold and Silver Rays.
In a press release, Consulate-General of Japan, Bengaluru highlighted Ms. Ganesh’s contribution to the spread of the Japanese language and culture in Karnataka.
The decision to confer the decoration is the first of its kind since the establishment of the Consulate-General of Japan in Bengaluru, the release stated.
Ms. Ganesh is also former President of the Bengaluru Chapter of Ohara-ryu Ikebana, and helped popularise not just the language but also other cultural traditions such as Ikebana, Japanese flower arrangements, and hosting exchange events.
As the Director of the Japanese Language School, Ms. Ganesh contributed to the spread of the language and trained candidates for the Japanese Language Proficiency Test course.
As an administrative executive of the “Lotus and Chrysanthemum Trust” whose establishment she has contributed to, Ms. Ganesh contributed enormously to the promotion of understanding and mutual understanding of both Japanese and Indian cultures, stated the release.
source: http://www.thehindu.com / The Hindu / Home> News> Cities> Bengaluru / by Special Correspondent / Bengaluru – April 30th, 2021
Test firing validated performance under extremely challenging scenarios, says DRDO
Indigenous Light Combat Aircraft (LAC) Tejas added the 5th generation Python-5 Air-to-Air Missile (AAM) to its air-to-air weapons capability after successful trials, the Defence Research and Development Organisation (DRDO) said on Wednesday.
“Trials were also aimed to validate enhanced capability of already integrated Derby Beyond Visual Range (BVR) AAM on Tejas. The test firing at Goa completed a series of missile trials to validate its performance under extremely challenging scenarios,” a DRDO statement said.
Derby missile achieved direct hit on a high speed manoeuvring aerial target and the Python missiles also achieved 100% hits, thereby validating their complete capability, it said. “The trials met all their planned objectives.”
Missile carriage flight tests
Prior to these trials, extensive missile carriage flight tests were conducted at Bengaluru to assess integration of the missile with aircraft systems on board the Tejas, like avionics, fire-control radar, missile weapon delivery system and the flight control system. At Goa, after successful separation trials, live launch of the missile was carried out on Tuesday.
“Python-5 missile live firing was conducted to validate target engagement from all aspects as well as beyond visual ranges. In all the live firings, missile hit the aerial target.” The missiles were fired from Tejas aircraft of the Aeronautical Development Agency flown by the IAF test pilots from the national flight test centre.
source: http://www.thehindu.com / The Hindu / Home> News> National / by Special Correspondent / New Delhi – April 28th, 2021
Technology developed by the Defence Research & Development Organisation (DRDO) will help them generate oxygen on site, to be given to needy patients.
The Medical Oxygen Plant technology, developed by DRDO | Express
Bengaluru :
Hospitals may soon no longer have to wait for medical oxygen to be transported from long distances. Technology developed by the Defence Research & Development Organisation (DRDO) will help them generate oxygen on site, to be given to needy patients.
The Medical Oxygen Plant (MOP) technology, developed by DRDO for on-board oxygen generation in the Light Combat Aircraft Tejas by DRDO’s Bengaluru-based Defence Bioengineering and Electromedical Laboratory (DEBEL), will now be employed in the fight against the current crisis of oxygen for Covid-19 patients. The same technology generates oxygen for fighter pilots flying the Tejas at high altitudes.
The oxygen plant is designed for a capacity of 1,000 litres per minute (LPM). It can cater to 190 patients at a flow rate of 5 LPM and refill 195 cylinders per day. The technology has already been transferred to Bengaluru-based Tata Advanced Systems Ltd and Coimbatore-based Trident Pneumatics Pvt. Ltd, which will be producing a total of 380 plants of 1,000 LPM capacity for installation across various hospitals in India. Another 120 oxygen plants of 500 LPM capacity will be produced by industries working with Indian Institute of Petroleum, Dehradun, coming under the CSIR, according to a Ministry of Defence release.
With DRDO tech, hospitals can make O2 in cost-effective way
The MOP technology is capable of generating oxygen with 93±3 per cent concentration which can directly be supplied to hospital beds or used to fill medical oxygen cylinders. It utilizes Pressure Swing Adsorption (PSA) technique and Molecular Sieve (Zeolite) technology to generate oxygen directly from atmospheric air. With the plants at their disposal, hospitals will be able to generate on-site medical oxygen in a cost-effective manner, rather than depend on suppliers from other places.
Apart from the Light Combat Aairaft fighter pilots, this oxygen plant has already proven its worth in preventing adverse health effects among jawans and officers of the Indian Army due to scarcity of oxygen in high altitude regions where they are posted in inaccessible and remote areas in the northern region. The MOP has already been installed at some of the Army sites in the North-East and Leh- Ladakh regions.
The plant complies with international standards like ISO 1008, European, US and Indian Pharmacopeia. Site preparation for five plants to be installed in Delhi/NCR region has al ready be e n initiated. The Defence Research and Development Organisation has initiated fabrication of 380 medical oxygen plants with release of supply orders for 332 units to Tata Advanced Systems and 48 to Trident Pneumatics Pvt. with a target of producing 125 plants per month under PM-CARES Fund. Secretary, Department of Defence R&D & Chairman, Defence Research and Developpment Organisation, Dr G Satheesh Reddy, has assured the support of DRDO for use of the technology by hospitals and other health agencies.
source: http://www.newindianexpress.com / The New Indian Express / Home> States> Karnataka / by Express News Service / April 29th, 2021
Karnataka on Monday announced free vaccination for COVID-19 for all those aged between 18 and 44 in government hospitals and centres from May 1.
Health Minister K. Sudhakar said ₹400 crore had so far been allocated for the purpose.
The government has been providing free vaccination to all those aged above 45 in government facilities, though there have been multiple complaints of vaccine shortage. Asked about vaccine availability, he said stocks based on orders were yet to come and more details would be released soon.
At a press conference on Monday, after the Chief Minister announced the decision, Dr. Sudhakar said with third and fourth waves being seen in other countries, the need was to vaccinate as many people as possible as soon as possible. “A sum of ₹81.32 crore has been allocated for COVID-19-related medicines, and ₹28 crore for Remdesivir,” he added.
source: http://www.thehindu.com / The Hindu / Home> News> States> Karnataka / by Staff Reporter / Bengaluru – April 27th, 2021
Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
Biocon Biologics has received approval for its cancer drug Abevmy co-developed with Viatris.
Abevmy 100 & 400 mg, a biosimilar of Bevacizumab has received marketing authorization approval from the European Commission (EC) following the positive recommendation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency, said the company in a filing to the stock exchange.
Abevmy is approved for treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway.
“The European Commission’s approval of our biosimilar Bevacizumab will enable us to offer this biologic therapy to cancer patients in the EU along with our partner Viatris. The addition of biosimilar Bevacizumab will strengthen our portfolio of biosimilars for cancer in the EU, which include biosimilar Trastuzumab and biosimilar Pegfilgrastim. This approval underlines our commitment to expand affordable access to life-saving biosimilars and make an enduring impact on global health,” said a company spokesperson.
source: http://www.economictimes.indiatimes.com / The Economic Times / Home> Business News> India> Healthcare> Biotech>Pharmaceuticals / ET Bureau / April 26th, 2021
